Seaside Therapeutics - LinkedIn
网页Seaside Therapeutics was founded to translate promising research discoveries into effective treatments for patients with autism, fragile X syndrome and other disorders of brain development. Our...
Allos Pharma – Late-stage Pharmaceutical Company
网页Most recently, he founded Seaside Therapeutics to leverage breakthrough scientific discoveries and develop therapeutics capable of correcting molecular perturbations that increase vulnerability to intellectual disability and autism.
Breaking News - Seaside Therapeutics & Roche Announce …
网页2012年6月19日 · Roche (SIX: RO, ROG; OTCQX: RHHBY) and Seaside Therapeutics announced today that they have entered into a collaboration to develop disease modifying treatments for Fragile X syndrome (FXS) and autism spectrum disorders (ASD), both neurodevelopmental disorders for which there are currently no effective pharmacological treatments that address ...
Allos Pharma secures exclusive license on arbaclofen in Fragile …
网页2020年11月19日 · Co-founders Mark Bear and Randy Carpenter previously founded Seaside Therapeutics and advanced arbaclofen through the Phase 3 trials in Fragile X Syndrome. This domain knowledge and expertise...
Seaside Therapeutics Company Profile 2024: Valuation, Funding ...
网页Developer of drug treatments designed for patients with brain development disorders. The company provides treatments for patients with autism, fragile X syndrome, and other disorders of brain development, enabling patients to …
Seaside gets $30M to pursue new autism drug | Fierce Biotech
网页2009年9月17日 · Cambridge, MA-based Seaside Therapeutics is emerging from stealth mode this morning with an announcement that it has raised $30 million to pursue mid-stage clinical trial development on new...
Roche and Seaside Therapeutics Announce Landmark Alliance to …
网页2012年6月19日 · Seaside Therapeutics is working to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders by translating breakthrough discoveries in neurobiology into...
Seaside Therapeutics Secures $30 Million Financing
网页2009年9月17日 · Seaside Therapeutics is changing this paradigm through scientific exploration that focuses on identifying the fundamental pathophysiology of brain development disorders and applying this...
Allos Pharma Revives Arbaclofen After 7 Years: New Hope for …
网页2020年11月19日 · Allos Pharma Revives Arbaclofen After 7 Years: New Hope for Fragile X Syndrome. May 2013 left many in the Fragile X community devastated when financial pressures led Seaside Therapeutics to stop developing an experimental drug, arbaclofen, for Fragile X syndrome (FXS). Today arbaclofen rises again!
Seaside Therapeutics Appoints Leading Industry ... - Fierce Pharma
网页2010年7月20日 · Seaside Therapeutics, Inc. is creating novel drug treatments to correct or improve the course of fragile X syndrome, autism and other neurodevelopmental disorders. The Company is dedicated to...
- 某些结果已被删除
跳至内容